# A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07667868/  
OnCo record `nct07667868` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of BP2202 run by BrightPath Biotherapeutics Co., Ltd., not yet recruiting.

## Summary

A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07667868 by BrightPath Biotherapeutics Co., Ltd., with 18 participants planned, started 2026-10-01. Conditions recorded: Relapsed/Refractory Multiple Myeloma (RRMM). Interventions recorded: BP2202.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07667868
- Phase: 1
- Setting: A Phase I, Open-Label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma
- Sponsor: BrightPath Biotherapeutics Co., Ltd.
- Enrolled: 18

## Sources

- ClinicalTrials.gov NCT07667868: https://clinicaltrials.gov/study/NCT07667868

## Connected records

- cancers: [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- drugs: [BP2202](https://onco.cc/drugs/bp2202/)
- companies: [BrightPath Biotherapeutics](https://onco.cc/companies/brightpath-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07667868.json